Currently out of the existing stock ratings of Jay Olson, 306 are a BUY (92.17%), 25 are a HOLD (7.53%), 1 are a SELL (0.3%).

Jay Olson

Work Performance Price Targets & Ratings Chart

Analyst Jay Olson, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 49.23% that have a potential upside of 37.28% achieved within 170 days.

Jay Olson’s has documented 724 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Industrials, Financial Services sectors.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 11-Nov-2024.

Wall Street Analyst Jay Olson

Analyst best performing recommendations are on NKTR (NEKTAR THERAPEUTICS).
The best stock recommendation documented was for NKTR (NEKTAR THERAPEUTICS) at 11/7/2019. The price target of $20 was fulfilled within 1 day with a profit of $1.3 (6.95%) receiving and performance score of 69.52.

Average potential price target upside

of $72.59 (51.87%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $53.32 (19.49%) on BIIB (BIOGEN).
of $50.57 (23.25%) on AMGN (AMGEN).

ACAD ACADIA Pharmaceuticals AMGN Amgen BCYC Bicycle Therapeutics Ltd BIIB Biogen CBAY Cymabay Therapeu CRSP Crispr Therapeutics AG EDIT Editas Medicine FREQ Frequency Therapeutics ICPT Intercept Pharmaceuticals MRTX Mirati Ther NBIX Neurocrine Biosciences NTLA Intellia Therapeutics PRTA Prothena plc PTLA Portola Pharmaceuticals SAGE Sage Therapeutic SGEN Seagen SRRA Sierra Oncology TXMD TherapeuticsMD ENTA Enanta Pharmaceuticals AXON Axon Enterprise . AYLA Ayala Pharmaceuticals DNLI Denali Therapeutics ETN Eaton PLC EXEL Exelixis FOCS Focus Financial Partners INCY yte JSPR Jasper Therapeutics KRTX Karuna Therapeutics MDGL Madrigal Pharmaceuticals NKTR Nektar Therapeutics BIVI Biovie CINC CinCor Pharma ETNB 89bio CGTX Cognition Therapeutics MDCO The Medicines Company RLMD Relmada Therapeutics RVMD Revolution Medicines VKTX Viking Therapeutics VYGR Voyager Therapeutics MRNS Marinus Pharmaceuticals GLTO Galecto

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Andrew Fein (HC WAINWRIGHT)